Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.

Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Knoll Pharma open offer: Pros and cons - Views on News from Equitymaster
  • E-MAIL
  • A  A  A
  • May 7, 2001

    Knoll Pharma open offer: Pros and cons

    Abbott Laboratories Inc has made an open offer to the shareholders of Knoll Pharma to acquire 20% of the company’s equity at Rs 328 per share. This follows Knoll Pharma’s parent company’s sell-out to Abbott Inc. Is it worth for Knoll Pharma shareholders to consider this option?

    Let’s take a look at a few things to evaluate this offer.

    • Knoll Pharma is a leading player in the domestic insulin, anti-diabetic, (with a market leadership in insulin therapy) pain control, and antacid market. Leading brands from the company’s stable include Brufen (anti- rheumatic), Diegen (anti-acid), Epilex (anti–epilepsy) and Cremmafin (laxative).

    • It has a high DPCO exposure of more than 62%. Imminent changes in industry led by dilution in DPCO would be a big upside for Knoll considering that 62 per cent of its turnover comes from price-controlled products. Moreover, company has received 22 per cent hike in insulin formulation which accounts for 41 per cent of turnover in 2000 – Rs 1.4 bn) in April 2001. This is expected to improve performance in FY 2001. Knoll Pharma : Better days ahead

    • Abbott Inc also has a 51% subsidiary viz, Abbott Laboratories India, which has major presence in vitamins, anti-infective, hospital and diagnostic products. Of the multinational pharma companies operating in India, Abbott is one of the few companies with a portfolio extending to hospital products and pediatric nutrition. The product portfolio of the company seems to be complimentary with Knoll Pharma.

    • At the current market price Knoll Pharma is trading at just 10 times its expected earnings for FY02.

    Shareholding Pattern of Knoll Pharma % of Holding
    Indian Promoters and Foreign Collaborators 56.7
    Institutions and Mutual Funds 14.3
    FII’s/GDR 3.3
    Free Float 25.7

    At the current market price of Rs 304, the open offer price (Rs 328) is at a 8% premium. Abbott will find it difficult to entice a 20% shareholding from the offer considering there is only 26% equity in free float. It seems unlikely that institutions would offer their stake for only an 8% premium considering that the long-term prospects of the company look good.

    There is a case for investors to continue holding their stock i.e. not opt for the open offer. This is mainly due to the business upside mentioned above. However, in view of the difference between the offer price and the market price, shareholders of Knoll Pharma can gain from arbitrage.

    Exercising the option gives the shareholder an immediate 8% upside. Existing shareholders could buy more stock in the market and submit their existing stock in the tender offer (i.e. arbitrage). The risk however is that their shares may not be accepted in the tender offer, under which circumstance they would be left holding more stock of Knoll Pharma. But if their shares are accepted, investors stand to make an immediate gain. However, an 8% premium to the market price doesn’t seem to be lucrative for Knoll Pharma shareholders.



    Equitymaster requests your view! Post a comment on "Knoll Pharma open offer: Pros and cons". Click here!


    More Views on News

    Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

    Aug 14, 2017

    A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

    Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

    Aug 14, 2017

    GST impact coupled with price erosion in US leads to lower profits for the quarter.

    Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

    Aug 8, 2017

    Profits plunge due to higher raw material costs.

    Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

    Jun 23, 2017

    Net Profit lower due to exceptional items in the previous year.

    Sun Pharma: Price Erosion in US Impacts Growth (Quarterly Results Update - Detailed)

    May 30, 2017

    US markets decline while other geographies grow in the quarter.

    More Views on News

    Most Popular

    Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

    Aug 7, 2017

    The data tells us quite a different story from the one the government is trying to project.

    A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

    Aug 10, 2017

    Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

    Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

    Aug 8, 2017

    Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

    Signs of Life in the India VIX(Daily Profit Hunter)

    Aug 12, 2017

    The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

    7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

    Aug 7, 2017

    Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

    Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
    Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

    LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

    SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

    Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
    Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407

    Become A Smarter Investor In
    Just 5 Minutes

    Multibagger Stocks Guide 2017
    Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
    We will never sell or rent your email id.
    Please read our Terms


    Aug 18, 2017 (Close)


    • Track your investment in ABBOTT INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
    • Add To MyStocks


    Detailed Financial Information With Charts